Company news

Akebia Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

October 29, 2026

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week

October 26, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

October 7, 2026

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

October 6, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

September 14, 2026

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

September 1, 2026

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

August 5, 2026

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

August 3, 2026

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

July 29, 2026

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

June 10, 2026

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

May 7, 2026

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

May 4, 2026

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

April 30, 2026

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

April 12, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

April 7, 2026

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

March 31, 2026

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

March 19, 2026

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

March 3, 2026

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

February 25, 2026

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

February 19, 2026

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 3, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2026

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

January 11, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

January 5, 2026

Akebia Announces Establishment of Rare Kidney Disease Pipeline

November 30, 2025

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

November 23, 2025

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 9, 2025

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

November 5, 2025

Akebia Therapeutics to Present at Upcoming Investor Conferences

November 3, 2025

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

October 29, 2025

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

October 27, 2025

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

October 19, 2025

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

August 20, 2025

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 6, 2025

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference

August 6, 2025

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

August 3, 2025

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

July 30, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

July 7, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

June 3, 2025

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 26, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 12, 2025

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

April 30, 2025

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

April 2, 2025

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

March 24, 2025

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

March 18, 2025

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

March 18, 2025

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.